Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 16/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 7/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973107 | 0.89 | APLNR (0.48) | PIM1PIM3PIM2APLNRNAMPT | |
| SCHEMBL3546998 | 0.73 | MEN1 (0.47) | PIM1PIM3PIM2 | |
| SCHEMBL13548687 | 0.73 | MEN1 (0.47) | PIM1PIM3PIM2 | |
| SCHEMBL3547001 | 0.70 | PIM1 (0.41) | PIM1PIM3PIM2APLNR | |
| SCHEMBL5662607 | 0.70 | MAP4K1 (0.41) | PIM1PIM3PIM2 | |
| SCHEMBL4974911 | 0.69 | HTR2C (0.64) | PIM1NAMPTSPR | |
| SCHEMBL5660759 | 0.69 | SPR (0.46) | NAMPTSPR | |
| SCHEMBL3538488 | 0.67 | TRPC3 (0.48) | PIM1PIM3PIM2 | |
| SCHEMBL3540061 | 0.66 | PIM1 (0.44) | PIM1PIM3PIM2 | |
| SCHEMBL3540062 | 0.65 | PIM1 (0.40) | PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | PIM1 1286/4885PIM3 1637/4885PIM2 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.